In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 3, 1998, Pages 389-392

  Verweij, Paul E ^a   Mensink, Marieke ^a   Rijs, Antonius J M M ^a   Donnelly, J Peter ^a   Meis, Jacques F G M ^a   Denning, David W ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DILUTION; DRUG RESISTANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REPRODUCIBILITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; ENVIRONMENTAL MICROBIOLOGY; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; TRIAZOLES;

EID: 0031688826     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.3.389     Document Type: Article

References (10)

1. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23, 608-15.
2. Sugar, A. M. (1990). Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use. Archives of Internal Medicine 150, 2258-64.
3. Denning, D. W., Radford, S. A., Oakley, K., Hall, L., Johnson, E. M. & Warnock, D. W. (1997). Correlation of in-vitro susceptibility testing of itraconazole with in-vivo outcome for Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy 40, 401-14.
4. Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A. et al. (1997). Itraconazole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 41, 1364-8.
5. Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A. et al. (1997). Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Journal of Clinical Microbiology 35, 139-43.
6. Dickinson, R. P., Bell, A. S., Hitchcock, C. A., Narayanaswami, S., Ray, S. J., Richardson, K. et al. (1996). Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl) butan-2-ol derivates with high activity against Aspergillus fumigatus. Bioorganic and Medicinal Chemistry Letters 16, 2031-6.
7. Oakley, K. L., Moore, C. B. & Denning, D. W. (1996). In vitro activity of voriconazole against Aspergillus spp. and comparison with amphotericin B and itraconazole. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996. Abstract F81, p. 114. American Society for Microbiology, Washington, DC.
8. Radford, S. A., Johnson, E. M. & Warnock, D. W. (1997). In-vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrobial Agents and Chemotherapy 41, 841-3.
9. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. (1997). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 41, 696-8.
10. Verweij, P. E., Oakley, K. L., Morrissey, J., Morrissey, G. & Denning, D. W. (1998). In vitro activity of LY303366 against amphotericin B susceptible and resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 42, 873-8.